|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 达昔单抗>> 市场分析报告 |
达昔单抗市场分析报告 |
|
Biogen Idec Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... COPAXONE) reference comparator arm. Daclizumab Daclizumab is a monoclonal antibody that ... tested in relapsing MS. A Phase 2b trial of daclizumab in MS, known as SELECT, is underway ... necessary for it to manufacture daclizumab. Fampridine Fampridine is an oral ... AbbVie Inc Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... levodopa), Anesthesia products and ZINBRYTA (daclizumab). Multiple Sclerosis - KOL Insight and Consensus Outlook Modules ... Laquinimod (Teva/Active Biotech) forecast Daclizumab HYP (Biogen/AbbVie) forecast Ocrelizumab ... Therapy Trends: Multiple Sclerosis An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends. Multiple Sclerosis: On the cusp of a ... Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018 Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H1 2018 SUMMARY According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H1 2018'; Interleukin 2 Receptor Subunit Alpha ... Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018 Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Pipeline Review, H2 2018 SUMMARY According to the recently published report 'Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2018'; Interleukin 2 Receptor Subunit Alpha ... Multiple Sclerosis: KOL Insight ... /Genzyme/Bayer HealthCare) MS Pipeline Zinbryta (daclizumab high-yield process, DAC-HYP ... Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question Report Includes: An introduction to interleukin-2 (IL-2) and identification of its applications Insights into the latest trends and technologies in the IL-2 research and development Discussion of strategies adopted by IL-2 developers for the successful ... Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019 Interleukin 2 Receptor Subunit Alpha - Pipeline Review, H2 2019 SUMMARY Interleukin 2 Receptor Subunit Alpha (TAC Antigen or p55 or CD25 or IL2RA) - Interleukin-2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in ... Multiple Sclerosis Therapies Market by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019–2026 ... expansion during the forecast period. Daclizumab, RG1594 (Ocrelizumab), and Lemtrada (Alemtuzumab ... BG-12) while others are injectable formulations (Daclizumab, Ocrelizumab, and Alemtuzumab), and all ... Consensus Outlook: Multiple Sclerosis Over the next five years, the global multiple sclerosis (MS) market is set to grow from $14.4 billion in 2012 to $18.3 billion in 2017. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient ... Therapy Trends: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules Charting the Future Multiple Sclerosis Market Landscape Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline ... KOL Insight: Multiple Sclerosis Recent launches of oral therapies have brought clinical advantages and clear patient benefits and are set to transform the treatment of Multiple Sclerosis (MS). The question is, which products will rise to become first choice treatments in relapsing forms ... Medical Affairs Reputations (US) [MS] ... ; Biogen) Tysabri (natalizumab; Biogen) Zinbryta (daclizumab; AbbVie/Biogen) A Competitive Assessment of Medical ... Market Access Impact (EU5) [MS] ... ; Biogen) Tysabri (natalizumab; Biogen) Zinbryta (daclizumab; AbbVie/Biogen) Exploring Market Access ... Market Access Impact (US) [MS] ... ; Biogen) Tysabri (natalizumab; Biogen) Zinbryta (daclizumab; AbbVie/Biogen) Exploring Market Access ... Innovative drugs: Mapping the pricing, reimbursement and HTA landscape ... Brivaracetam Brodalumab Cerliponase Alfa Crisaborole Daclizumab Daratumumab Defibrotide Deflazacort Delafloxacin Dupilumab ... Charting the Global Biosimialr pipeline ... Anakinra Bevacizumab Certolizumab Pegol Cetuximab Daclizumab Darbepoetin Alfa Denosumab Eculizumab Enoxaparin ... Multiple Sclerosis [2016]: Bulletin #3 ... ) provisionally restricting the use of Zinbryta (daclizumab; Biogen/AbbVie) due to a patient’s death ... BIOGEN IDEC - Dominating Multiple Sclerosis Market for Long Term! ... by the data presented at ECTRIMS ‘11 on BG-12 and Daclizumab (stock up by 6-8%). We expect the earnings also ... of ~$1.3b), and with Tysabri, Famprya, BG-12 (PhIII), Daclizumab (PhII), PEG-IFN b-1a (PhIII), BIIB ... |